Two Sigma Advisers LP Increases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Two Sigma Advisers LP lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 212,500 shares of the company's stock after purchasing an additional 24,100 shares during the period. Two Sigma Advisers LP owned about 0.68% of Medpace worth $70,599,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. R Squared Ltd purchased a new position in Medpace in the fourth quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace in the fourth quarter valued at $31,000. Jones Financial Companies Lllp raised its stake in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC raised its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares in the last quarter. Finally, Assetmark Inc. raised its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on MEDP. Truist Financial cut their price target on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and cut their price target for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Finally, Robert W. Baird cut their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of "Hold" and an average price target of $349.30.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now owns 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 20.30% of the stock is currently owned by insiders.

Medpace Price Performance

Shares of MEDP traded up $1.86 during midday trading on Friday, reaching $294.89. 266,217 shares of the stock were exchanged, compared to its average volume of 354,458. The business's 50-day moving average price is $301.83 and its 200 day moving average price is $326.78. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the previous year, the firm posted $3.20 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.